Plain-English translation of NCT06617481 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing an advanced imaging scan called Posluma (flotufolastat PET scan) to detect prostate cancer that may have come back after prostate removal surgery. The medication is already approved by the FDA, but researchers want to learn how well it works for patients with very early signs of recurrence. This type of scan may be better at finding cancer in men with low PSA levels compared to other imaging tests currently available.
After prostate removal surgery, some men develop rising PSA levels that suggest cancer may have returned, but standard imaging scans often cannot find the cancer at these early stages. This trial exists to confirm whether this imaging scan can reliably detect cancer when PSA levels first start rising, which could help doctors start treatment sooner.
You likely qualify if…
You likely don't qualify if…
You will receive an advanced imaging scan called a PET scan with the medication Posluma. If the first scan does not show cancer but your PSA level rises further by more than 0.1 ng/ml, you may have a second scan. The study involves a small group of 30 men and is currently recruiting participants at AdventHealth locations.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
AdventHealth
Collaborators
Blue Earth Diagnostics
Enrollment target
~30 participants
Started
September 2024
Primary completion
September 2027
Age range
18 Years and older
Sex
Male only
Last updated on clinicaltrials.gov in October 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
AdventHealth AdventHealth Oncology Research
AdventHealth
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.